Which vitamin will reduce the therapeutic effects of levodopa?

A. B6 (Pyridoxine):

Vitamin B6, also known as pyridoxine, is known to reduce the therapeutic effects of levodopa. It competes with levodopa for absorption in the gastrointestinal tract and can decrease the amount of levodopa that reaches the brain, thereby diminishing its effectiveness in treating Parkinson's disease symptoms.

B. A (Retinol):

Vitamin A, also known as retinol, is not typically associated with reducing the therapeutic effects of levodopa. Vitamin A plays important roles in vision, immune function, and cellular communication, but it does not interact with levodopa in a way that affects its therapeutic efficacy.

C. E (Alpha-Tocopherol):

Vitamin E, also known as alpha-tocopherol, is an antioxidant that plays a role in protecting cells from oxidative damage. While vitamin E supplementation is sometimes used in Parkinson's disease management for its potential neuroprotective effects, it is not known to reduce the therapeutic effects of levodopa.

D. K (Phylloquinone):

Vitamin K, also known as phylloquinone, is primarily involved in blood clotting and bone metabolism. It does not interact with levodopa in a way that reduces its therapeutic effects.

E. C (Ascorbic Acid):

Vitamin C, also known as ascorbic acid, is not known to reduce the therapeutic effects of levodopa. While vitamin C has various roles in the body, including antioxidant activity and immune function support, it does not interfere with levodopa absorption or efficacy.

A.Computerized tomography angiography (CTA)

This is a likely diagnostic test that the provider may prescribe. CTA uses computed tomography (CT) imaging to visualize the blood vessels in the brain and neck. It can help identify areas of stenosis, occlusion, or other abnormalities in the blood vessels that may contribute to the TIA symptoms.

B. Complete blood count (CBC)

A complete blood count (CBC) is a routine laboratory test that assesses various components of blood, such as red blood cells, white blood cells, and platelets. While it may not be specific to diagnosing a transient ischemic attack (TIA), it can help evaluate for underlying conditions such as anemia or thrombocytosis that could contribute to TIA symptoms or increase the risk of stroke.

C. Prothrombin time (PT)

Prothrombin time (PT) is a laboratory test that evaluates the clotting ability of blood and is typically used to monitor anticoagulant therapy. While abnormal coagulation parameters may be associated with certain conditions that predispose to TIA (such as atrial fibrillation), PT alone is not a specific diagnostic test for TIA.

D. Transesophageal echocardiogram (TEE)

This is another possible diagnostic test that the provider may prescribe. TEE is a specialized echocardiogram that provides detailed images of the heart structures by inserting an ultrasound probe